ClinicalTrials.gg
Not yet recruitingNCT06559670Updated Aug 19, 2024

Prevention of Chronic Lung Disease (CLD - Prevention Study)

An interventional study of Blood sampling in Chronic Lung Disease, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Not yet recruiting at 1 site in Italy. Open to participants aged 1 Hour to 24 Hours. Per ClinicalTrials.gov, last updated 2024-08-19.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
1 Hour to 24 Hours
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy — 42 open to participants now, 48 under way, 8 of them phase 3. Pulmonary Disease, Chronic Obstructive · Italy.

Planned enrollment
168th of 212
42 · median 245
Started
2024
with 16 others
No phase
77 of 280
17 open now
Primary completion
2025-01
later than 7 of 47 live
Registered
253rd of 280
by date

Among the 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy, this one is the 168th largest by planned enrollment of the 212 interventional ones that give a count, is one of 17 that started in 2024, is one of 77 with no phase, reaches primary completion later than 7 of the 47 other live ones, and was the 253rd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

42 of the 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 1 Hour to 24 Hours · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 280 studies in Pulmonary Disease, Chronic Obstructive with a site in Italy, or all of them as a file.
02

Study summary

Primary endpoint:

  • prospectively identify potential biomarkers able to predict the severe course of pulmonary funcion in the first 12 months of life and realize a new profile to early identify hugh risk newborns

Secondary endpoints:

  • detect genetic variance causation model (by MiSeq Illumina platform) correlating with severe pulmonary dysfunction and asthma development;
  • detect MIcroRNAs as well as anti- and pro-inflammatory cytokine variations (MIP-1α, MCP-1, IL-8, TNF-α, IFN-ɣ, IL-10) correlating with the severity of pulmonary dysfunction in the first 12 months of life and the risk of asthma development

Population: preterm infants with gestational age \< 32 weeks who have suffered from acute respiratory insufficiency at birth

Intervention:

  • Assessment of prenatal risk factors.
  • Collection of the following biological specimens: 1) a vaginal swab from the mothers of enrolled infants 2) a placenta sample 3) an arterial or venous cord blood sample at birth 4) peripheral blood samples from enrolled infants: the first within 48 hours of life, the subsequent ones at 7 and 28 days of life and at 6 and 12 months of age 5) bronchoalveolar lavage (BALF) samples exclusively in infants intubated for clinical reasons within the first 24 hours of life, at 7 and 28 days of life. 6) first meconium sample issued and subsequent stool samples at 7 and 28 days of life and at 6 and 12 months of age, of enrolled infants
  • Respiratory Functionality Testing at 6 and 12 months of age
Read the detailed description

Background Chronic Lung Disease (CLD) is one of the most common complications of perinatal lung injury which represents a systemic condition with long term sequelae, such as persistent pulmonary dysfunction, asthma-like symptoms, and BPCO. CLD recognizes many prenatal risk factors, including maternal smoking, chorioamnionitis, and intrauterine growth restriction (IUGR), besides postnatal risk factors such as hyperoxia, parenteral nutrition, inflammation and mechanical ventilation. Exposure to inflammation in utero alters neonatal immune development and predisposes the fetal lung to a dysregulated prolonged response to invasive mechanical ventilation and supraphysiological oxygen. Responses to injurious (and protective) influences early in life are modulated by genetic and epigenetic mechanisms, that could result in permanent structural changes with significant consequences in adulthood. IUGR pregnancies are characterized by increased oxidative stress and IUGR infants are at high risk of cardiovascular disease, metabolic syndrome, lung dysfunction and chronic kidney and respiratory diseases in adulthood Despite the constant increase in knowledge of the mechanisms leading to the progression of lung damage, so far, no effective management has been developed that would lead to CLD prevention.

Aims

  1. prospectively identify potential biomarkers able to predict the severe course of pulmonary function in the first 12 months of life and realize a new profile to early identify high risk newborns.
  2. detect genetic variance causation model (by MiSeq Illumina platform) correlating with severe pulmonary dysfunction and asthma development.
  3. detect MicroRNAs as well as anti- and pro-inflammatory cytokine variations (MIP-1a, MCP-1, IL-8, TNF-a, IFN-g, IL-10) correlating with the severity of pulmonary dysfunction in the first 12 months of life and the risk of asthma development.

Experimental design This is a multicenter longitudinal study, whose primary aim is to identify a new high-risk neonatal profile for Chronic Lung Disease (CLD) development, starting from perinatal life. In order to reach this objective all participant Units will perform vaginal swab to the enrolled mothers, will collect placenta and cord blood at birth and peripheral blood, bronchoalveolar lavage fluid (BALF), meconium and feces samples of all enrolled newborn infants. The study will begin with the evaluation of prenatal risk factors.

After delivery the placentas will be fixed in 10% buffered formalin. Subsequently macroscopic and microscopic analyses will be performed according to the Amsterdam placental workshop group consensus statement. A vaginal swab will be collected at the time of delivery for all the enrolled women. Three ml of cord blood (artery and/or vein) will be performed for analysis of miRNA, genetic variance and cytokines. In intubated infants only, BALF sample will be obtained by instilling 1 ml/kg of 0.9% sodium chloride in the endotracheal tube and suctioning the fluid into a sterile mucus trap. The first BALF sample will be collected within the first 24 h of life, whereas further BALF samples will be collected at 7 and 28 days of life in newborns who will be still intubated. First meconium sample after birth and additional feces samples will be collected at 7, 28 days of life, 6 and 12 months of life. Vaginal swabs, placenta, BALF, meconium and feces samples will be stored at -80°C until further processing. For each sample, bacterial DNA extraction will be performed in a strictly controlled level-2 biological safety workplace using DANAGENE MICROBIOME DNA kits (Danagen-Bioted) according to manufacturers instructions.

In cord serum at birth (artery) and at 48 hours of life, 8-10 candidate miRNAs, in particular miR-451, miR-29b, and miR-16 will be studied as it has been shown that they have an inhibitory effect on angiogenesis through vascular endothelial growth factor (VEGF) suppression and miR is associated to genetic susceptibility to CLD. The genetic variance causation model will be performed in all enrolled newborns at 48 hours of life (at least 500 μL of whole blood) using a MiSeq Illumina platform allowing application of Next Generation Sequencing technologies.

To detect anti- and pro-inflammatory cytokine variations correlating with the severity of disease over time, cord blood and peripheral blood samples (2 ml into an EDTA tube) will be obtained from the included infants at the admission (within 48 hours of life), at 7 and 28 days of life, at 6 and 12 months. Both anti- (INF-y) and pro-inflammatory (IL-6 and NGF) cytokines levels will be investigated. All samples will be stored at -80 °C until testing. Cytokines will be measured with a commercially available ELISA kit according to manufacturer's instructions.

The investigators will also try to explore the association between mother and placenta data with newborns analysis during the first days of life. Upon newborn admission to Neonatal Intensive Care Unit, considerable attention will be paid to ascertaining the degree and variations in hemo-oxygenation, as well as the presence of infection that is at the origin of Oxidative Stress (OS) and OS- related diseases. The following specimens will be collected: 1 ml of peripheral blood (within 48 hours of life). Additional peripheral blood samples will be collected at 7 and 28 days of life, at 6 and 12 months of life.

Oxidative stress (OS) and lipid mediators involved in OS will be evaluated both by biomarkers of oxidative protein damage (Advanced Oxidation Protein Products, AOPP) and lipid peroxidation (Isoprostanes, IsoPs). A further evaluation of oxidative stress profile will be performed by measuring non-enzymatic antioxidant molecules (vitamin E; glutathione, GSH, and ascorbic acid, AA) and enzymatic antioxidant molecules (superoxide dismutase, SOD, catalase, CAT, and glutathione peroxidase, GPx). To this end high-performance liquid chromatography (HPLC) and gas chromatography interfaced mass spectrometry (GC-MS) will be employed: HPLC to detect vitamin E, glutathione, GSH, and AA.

The final step will be prospectively identify a new profile of high risk newborns for severe pulmonary dysfunction in the first 12 months of life, at higher risk of developing asthma and COPD in later age. A long term outcome of all enrolled babies will be performed to unravel the relationships between placenta analysis, miRNA expression, inflammation and microbiota - as part of the in utero exposome (chorioamnionitis or fetal growth restriction) and oxidative stress with inflammation - as part of postnatal factors (invasive respiratory support, Patent Ductus Arteriosus, pneumonia, sepsis) - with the pulmonary outcome in terms of abnormal pulmonary function at 6 and 12 months of age.

At 6 and 12 months of age, the infants will receive clinical and pulmonary evaluation. Pulmonary function test (PFT) will be performed in all enrolled infants and will include Tidal breathing analysis and Nitrogen Washout test. The infants will be placed in the supine position, during quiet, natural sleep, according to American Thoracic Society/European Respiratory Society recommendations with measurement of lung volumes, flow, functional residual capacity, Lung Clearence Index 5% (LCI 5), Lung Clearence Index 2.5% (LCI 2.5), time to peak tidal expiratory flow/expiratory time ratio (tPTEF/tE). Lung ultrasound will be performed to rule out lung abnormalities. After allowing adaptation to the mask, tidal breathing, flow volume loops for >2 minutes or >20 artifact free breaths will be recorded. PFT will be made in order to relate the functional respiratory data with those of generated biochemical profile. Any possible relationships among pulmonary function, biochemical markers just before birth and in the infants at 6-12 months of age, and anthropometric measurements will be studied. Pulmonary development and function during extrauterine life will be related with prenatal measurements. Data in appropriate for gestational age (AGA) infants, small for gestational age (SGA) infants and large for gestational age (LGA) infants will be compared.

Methods of data collection Several types of data will be collected including quantitative, qualitative, generated from imaging, tissue and blood samples. Clinical data for Aim 1, 2 and 3 will be collected and managed using REDCap electronic data capture tools hosted at UO1- Fondazione Policlinico Universitario A. Gemelli-IRCCS (https://redcap-irccs.policlinicogemelli.it/).

A dedicated electronic case report form (eCRF) will be developed. Pseudo-anonimyzed data will be collected from the units involved. The Investigator will be responsible to ensure that the eCRF is properly and completely filled in. Sources of clinical information include the physicians patient record, hospital notes, original laboratory records, pharmacy records, results of ultrasound examination etc.

Statistic plan Primary endpoint of the study is to identify whether clinical, demographic, laboratory, and other parameters are able to predict the development of chronic lung disease at 36 weeks of PMA and/or of abnormal pulmonary function at 12 months of age. Assuming an acceptable accuracy level, with an Area Under the ROC Curve of at least 0.75 ± 0.15, a sample size of 42 patients is required.

Statistical analysis The sample will be described in its clinical and demographic characteristics using the appropriate descriptive statistics indices. In depth, qualitative data will be expressed as absolute and relative percentage frequency, while quantitative variables as either mean and standard deviation (SD) or median and interquartile range (IQR), depending on the case. To verify the Gaussian distribution of quantitative variables the Shapiro-Wilk test will be applied. Differences between groups at baseline will be evaluated, with regard to qualitative data, by either the Chi-Squared test or the Fisher-Freeman-Haltons exact test, as appropriate. Quantitative data will instead be compared using Student's t test for independent samples or Mann Withney's nonparametric U test, depending on the data distribution. Violin plots will be used to graphically represent significant or clinically relevant differences. The evaluation of the difference in terms of primary outcome at 12 months will be evaluated by Kaplan-Meier survival analysis. In particular, the log-rank test will be applied, and appropriate cumulative incidence curves will be drawn. In order to assess potential predictors of the primary outcome at 12 months, uni- and multivariable Cox regression models will be fitted. In depth, the potential predictors of the outcome will be evaluated by means of ordinary proportional hazard Cox regression models, and the Hazard Ratios (HR) and the 95% confidence intervals (CIs) will be consequently reported. The proportionality of the hazard functions will be evaluated by visual inspection of the hazards and Schoenfeld residual plots. In case of doubtful proportionality, Cox weighted regression models will be fitted. Predictors to be included in the multivariable model will be selected based on the univariable analysis (p\<0.05 or suggestive, i.e. 0.05 p \<0.10) and expert opinion, consistent with the rule of at least 10 events by outcome variable, and TRIPOD recommendations. The performance of the model will be evaluated by several indices, such as Cindex, Somers Dxy-rank correlation, Nagelkerke's R2 value, calibration intercept and slop. The C-index can be interpreted as an AUC, i.e. a measure of the accuracy of the model. Statistical significance is set for values of p\<0.05. Suggestive p values (0.05, p \< 0.10) will also be reported. Statistical analyses will be conducted using STATA (StataCorp, USA) and R (https://www.r-project.org/).

03

Conditions studied

  • Chronic Lung Disease

Keywords

  • Chronic Lung Disease
  • Newborns
  • COPD
  • Preterm infants
  • Bronchopulmonary dysplasia
04

Who can participate

Ages eligible
1 Hour to 24 Hours
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Infants with gestational age \< 32 weeks with at least one of the following signs of acute respiratory failure within the first 24 hours of life:

  • need for mechanical ventilation;
  • need for noninvasive respiratory support;
  • need for oxygen administration;
  • need for surfactant administration

Exclusion criteria

Exclusion Criteria:

  • Congenital malformations
  • Neuromuscular diseases.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Other
    Preterm babies

    All the newborns will be studied to identify babies who will develop later (at 36 weeks of postcomptional age) Chronic Lung Disease of prematurity

    Other: Blood sampling

Interventions

  • OtherBlood sampling

    - Collection and analysis of blood samples

06

What researchers measure

Primary outcomes

  1. Identification of biomarkers of a severe course of pulmonary function by the study of microbiome and of oxidative stress

    8-10 candidate MIcroRNAs (absolute levels), particularly miR-451, miR-29b and miR-16, will be studied on serum obtained from cord blood and blood sampling of the newborn at 48 hours of life. To detect changes in anti- and pro-inflammatory cytokines (MIP-1α, MCP-1, IL-8, TNF-α, IFN-ɣ, IL-10; pg/ml) correlated with disease severity over time, cord blood will be used, and peripheral blood samples (2 ml in an EDTA tube) will be taken from enrolled infants by 48 hours of life, at 7 and 28 days of age, and at 6 and 12 months of age. Cytokines will be assayed by commercially available ELISA kit according to the manufacturer's instructions and will be expressed in pg/ml.

    Time frame: 12 months

Secondary outcomes

  1. Analysis of genetic variance causation model in patients with and without severe pulmonary dysfunction and asthma development

    Genetic variance causality modeling will be performed in all enrolled infants at 48 hours of age (500 μL whole blood), using a MiSeq Illumina platform that enables the application of next-generation sequencing technologies.

    Time frame: 12 months

Other outcomes

  1. MIcroRNAs (miR) and anti- and pro-inflammatory cytokine levels in patients with and without respiratory symptoms in the first 12 months of life

    8-10 candidate MIcroRNAs (absolute levels), particularly miR-451, miR-29b and miR-16, will be studied on serum obtained from cord blood and blood sampling of the newborn at 48 hours of life. To detect changes in anti- and pro-inflammatory cytokines (MIP-1α, MCP-1, IL-8, TNF-α, IFN-ɣ, IL-10; pg/ml) correlated with disease severity over time, cord blood will be used, and peripheral blood samples (2 ml in an EDTA tube) will be taken from enrolled infants by 48 hours of life, at 7 and 28 days of age, and at 6 and 12 months of age. Cytokines will be assayed by commercially available ELISA kit according to the manufacturer's instructions and will be expressed in pg/ml.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • van Smeden M, Moons KG, de Groot JA, Collins GS, Altman DG, Eijkemans MJ, Reitsma JB. Sample size for binary logistic prediction models: Beyond events per variable criteria. Stat Methods Med Res. 2019 Aug;28(8):2455-2474. doi: 10.1177/0962280218784726. Epub 2018 Jul 3. PubMed 29966490 ↗
  • Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015 Jan 7;350:g7594. doi: 10.1136/bmj.g7594. PubMed 25569120 ↗
  • Yang H, Wang K. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat Protoc. 2015 Oct;10(10):1556-66. doi: 10.1038/nprot.2015.105. Epub 2015 Sep 17. PubMed 26379229 ↗
  • Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-24. doi: 10.1038/gim.2015.30. Epub 2015 Mar 5. PubMed 25741868 ↗
  • Negi R, Pande D, Karki K, Kumar A, Khanna RS, Khanna HD. A novel approach to study oxidative stress in neonatal respiratory distress syndrome. BBA Clin. 2014 Dec 8;3:65-9. doi: 10.1016/j.bbacli.2014.12.001. eCollection 2015 Jun. PubMed 26676080 ↗
  • Kellner M, Noonepalle S, Lu Q, Srivastava A, Zemskov E, Black SM. ROS Signaling in the Pathogenesis of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS). Adv Exp Med Biol. 2017;967:105-137. doi: 10.1007/978-3-319-63245-2_8. PubMed 29047084 ↗
  • Cannavo L, Perrone S, Viola V, Marseglia L, Di Rosa G, Gitto E. Oxidative Stress and Respiratory Diseases in Preterm Newborns. Int J Mol Sci. 2021 Nov 19;22(22):12504. doi: 10.3390/ijms222212504. PubMed 34830385 ↗
  • Tirone C, Paladini A, De Maio F, Tersigni C, D'Ippolito S, Di Simone N, Monzo FR, Santarelli G, Bianco DM, Tana M, Lio A, Menzella N, Posteraro B, Sanguinetti M, Lanzone A, Scambia G, Vento G. The Relationship Between Maternal and Neonatal Microbiota in Spontaneous Preterm Birth: A Pilot Study. Front Pediatr. 2022 Jul 22;10:909962. doi: 10.3389/fped.2022.909962. eCollection 2022. PubMed 35935374 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2024; primary completion for Jan 2025, 4 months later.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 4 months is below that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2024
First posted
Aug 19, 2024
StartEst.
Sep 2024
Primary completionEst.
Jan 2025
CompletionEst.
Sep 2026
Last update
Aug 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06559670
Collaborators
Azienda Ospedaliera Universitaria Policlinico "G. Martino", Azienda Ospedaliero-Universitaria di Parma, Ospedali Riuniti di Foggia
Responsible party
VENTO GIOVANNI (Chief UOC of Neonatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) — Principal investigator
First posted
Aug 19, 2024
Start date
Sep 2024 (estimated)
Primary completion
Jan 2025 (estimated)
Completion
Sep 2026 (estimated)
Last update
Aug 19, 2024

Study contacts

Giovanni Vento
Contact
giovanni.vento@unicatt.it
+390630153237
Giovanni Vento
principal investigator · Fondazione Policlinico Universitario A. Gemelli, IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion